A similar result was observed in the HERALD study, in which patritumab appeared to restore sensitivity to erlotinib in patients with high HRG levels.52 It remains to be seen if BTC emerges as an important biomarker for seribantumab in EGFR dependent cancers like colon or head and neck cancer. The gene discussed is EGFR; the disease is cancer.